US 10556891
Compositions and methods for inhibition of the JAK pathway
granted A61KA61K31/155A61K31/506
Quick answer
US patent 10556891 (Compositions and methods for inhibition of the JAK pathway) held by Rigel Pharmaceuticals, Inc. expires Mon Feb 06 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Rigel Pharmaceuticals, Inc.
- Grant date
- Tue Feb 11 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Feb 06 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 15
- CPC classes
- A61K, A61K31/155, A61K31/506, A61K31/5377, A61K31/538